IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
24.86
-0.16 (-0.64%)
At close: Jul 29, 2025, 4:00 PM
24.84
-0.02 (-0.08%)
After-hours: Jul 29, 2025, 5:07 PM EDT
IDEAYA Biosciences Revenue
IDEAYA Biosciences had revenue of $7.00M in the twelve months ending March 31, 2025, down -54.85% year-over-year. In the year 2024, IDEAYA Biosciences had annual revenue of $7.00M, down -70.07%.
Revenue (ttm)
$7.00M
Revenue Growth
-54.85%
P/S Ratio
311.04
Revenue / Employee
$53,435
Employees
131
Market Cap
2.18B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.00M | -16.39M | -70.07% |
Dec 31, 2023 | 23.39M | -27.55M | -54.08% |
Dec 31, 2022 | 50.93M | 22.99M | 82.28% |
Dec 31, 2021 | 27.94M | 8.40M | 43.01% |
Dec 31, 2020 | 19.54M | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IDYA News
- 5 days ago - IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma - PRNewsWire
- 6 days ago - IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy - PRNewsWire
- 7 days ago - IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC - PRNewsWire
- 8 days ago - IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 2 months ago - IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events - PRNewsWire
- 2 months ago - Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 - Seeking Alpha
- 3 months ago - IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - PRNewsWire